21

April

Seattle Genetics Announces U.S. FDA Approval of TUKYSA™ (tucatinib) for People with Advanced Unresectable or Metastatic HER2-Positive Breast Cancer

Seattle Genetics, Inc. is pleased to inform you that on April 17, 2020, the FDA approved TUKYSA tablets for oral administrationTUKYSA is a kinase inhibitor indicated in combination with trastuzumab and capecitabine for treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer, including patients with brain metastases, who have received one or more prior anti-HER2-based regimens in the metastatic setting.

Please see attached full Prescribing Information HERE

Below is the product information needed to load TUKYSA.

NDC

51144-002-60

TUKYSA

(tucatinib) 150mg

Yellow, caplet-shaped tablet

TUC embossed on one side, 150 on other side

60 count tablets/bottle

NDC

51144-001-60

TUKYSA

(tucatinib) 50mg

Yellow, round-convex tablet

TUC embossed on one side, 50 on other side

60 count tablets/bottle

TUKYSA can be ordered through the following Specialty Distributors:

ASD Healthcare

McKesson Plasma & Biologics

Cardinal Health

McKesson Specialty Health

Oncology Supply

Click here to learn more.

Victoria

Victoria has blogged 1090 posts